A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
Sponsor: Amgen
Listed as NCT06660173, this PHASE2 trial focuses on Type 2 Diabetes Mellitus (T2DM) and remains ongoing. Sponsored by Amgen, it has been updated 10 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alzira, Spain , Anaheim, United States , Athens, Greece , Austin, United States , Baja, Hungary , Balatonfüred, Hungary , Bari, Italy , Bialystok, Poland , Birmingham, United States and 71 more locations